[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652617":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":36,"locations":46,"responsibleParty":64,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":25,"enrollmentInfo":79,"targetDuration":25,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":97,"whyStopped":25,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Contingency Management","EXPERIMENTAL","Receiving social drivers screening, all standard clinical care, and contingency management",[13,14],"Behavioral: Contingency Management","Other: Social Drivers of Health Screening",{"label":16,"type":17,"description":18,"interventionNames":19},"Usual Care","ACTIVE_COMPARATOR","Receiving social drivers screening and all standard clinical care",[14],[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","12 weekly sessions, 15-20 minutes each",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Social Drivers of Health Screening","Screening for social drivers of health, documentation of applicable z-codes in the medical record and social needs linkage",[9,16],[31,34],{"name":32,"affiliation":5,"role":33},"Jeannie C Kelly, MD, MS","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":5,"role":33},"Ana A Baumann, PhD",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":25,"email":41},"Melissa Mills","CONTACT","(557) 234-9066","melissa.mills@wustl.edu",{"name":43,"role":39,"phone":44,"phoneExt":25,"email":45},"Emily Diveley, RN, BSN","(314) 362-4685","diveley@wustl.edu",[47],{"facility":48,"status":25,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Washington University","St Louis","Missouri","63110","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-90.19789,38.62727,{"lat":58,"lon":57},[61,63],{"name":62,"role":39,"phone":40,"phoneExt":25,"email":41},"Melissa Mills, BS",{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":65,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[67],{"name":68,"class":6},"University of Maryland, Baltimore","100652617","phase-2-substance-use-in-pregnancy---optimizing-retention-in-treatment-by-maximizing-opportunities-for-management-100652617",false,"NCT07776457","Substance Use in Pregnancy - Optimizing Retention in Treatment by Maximizing Opportunities for Management","Substance Use in Pregnancy- Optimizing Retention in Treatment by Maximizing Opportunities for Management","SUPPORT MOM","Inclusion Criteria:\n\n* Confirmed viable intrauterine pregnancy at any gestational age; OR postpartum with at least six months remaining until 365 days after deliver\n* Diagnosis of SUD as defined by DSM-5 and\u002For as documented in the clinical record\n* 18 years of age or older\n* Two or more positive domains in first screening for social drivers of health\n* Receiving ongoing care at participating study site\n\nExclusion Criteria:\n\n* Declining follow-up care at participating study site\n* Participated in R61 pilot study for CM\n* Requiring immediate hospitalization for unstable medical or psychiatric conditions making patient clinically unsuitable for research participation at the time of enrollment approach\n* Unable to participate in English","FEMALE","18 Years",{"count":80,"type":81},245,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","Overdose is a national top-three leading cause of pregnancy-associated death, and maternal substance use disorder (SUD) accounts for an estimated $1.5 billion in healthcare spending each year. Treatment with medication and behavioral therapy lowers morbidity and overdose risk. However, studies have shown 55% to 80% of patients stop treatment within one year postpartum. Additionally, as a result of systemic inequities, historically marginalized patients are at greatest risk of overdose or death. We are conducting a study at WashU Medicine and University of Maryland, Baltimore clinics that offer prenatal care, addiction treatment, and extended postpartum support for patients facing the challenges of a SUD. Study participants will complete a structured screening and management of their social needs, and then will be randomly assigned to continue their usual care or to participate in a contingency management program, which provides incentives to continue treatment.",[87,88],"Pregnancy","Substance Use Disorder (SUD)",[90,91,92,93,94,95,96],"randomized","pregnancy","prenatal","substance use disorder","contingency management","postpartum","intervention","NOT_YET_RECRUITING","2026-08-17",{"date":100,"type":101},"2026-08-20","ACTUAL",{"date":103,"type":81},"2027-01",{"date":105,"type":81},"2030-02",{"name":5,"class":6},1]